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Summary We assayed methyl-p-hydroxyphenyllactate esterase (MeHPLAase) activity in 63 cases of primary laryngeal squamous cell
carcinoma. MeHPLAase activitydid notshowanycorrelation with oestrogen, progesterone andepidermalgrowth factor(EGF) receptorlevels. No
significant relationship was found between MeHPLAase activity and age, sex, tumour site, T classification, stage of disease and EGFR status,
whereas a significant inverse relationship was found between enzymatic activity and neck lymph node positivity at presentation. The median
value of MeHPLAase activity tended to be higher in tumours with low histopathological grade than in those with high histopathological grade.
Dunng the follow-up period (median 50 months, range 2-90 months) locoregional recurrences were observed in 31 outof63 (49%) cases. Atthe
end of the study, 27 out of 63 (43%) patients had died of cancer. Cox univarate analysis using MeHPLAase activity as a continuous covariate
showed that the levels of enzymatic activity were inversely associated with the risk of death and relapse. Assuming the mean value of enzymatic
activity as the cut-off value, we found a statistically significant relationship between high MeHPLAase activity and longer relapse-free and overall
survival. MeHPLAase activity status retained its prognostic significance also in the lymph node-negative subgroup of patients. On multivariate
analysis, both EGFR and MeHPLAase activity proved to be independent factors for predicting a short relapse and the overall survival.
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Methyl-p-hydroxyphenyllactate (MeHPLA), probably derived
from cell metabolism (Griffiths and Smith, 1972), has been identi-
fied as the true endogenous ligand oftype II oestrogen binding sites
(type II EBS) (Clark et al, 1978; Markaverich et al, 1988a), which
are expressed in many normal and malignant tissues (Ranelletti et
al, 1988, 1992; Piantelli et al, 1993; Ferrandina et al, 1993). It has a
high binding affinity (dissociation constant = 4-5 nM) for type II
EBS and inhibits the oestradiol-stimulated growth of rat uterus
and MCF-7 human breast cancer cells (Markaverich et al,
1988a, 1990). MeHPLA is hydrolysed by MeHPLA esterase
(MeHPLAase) to the free p-hydroxyphenyllactic acid (HPLA),
which has a much lower binding affinity for type II EBS and is
inactive in terms of cell growth inhibition (Markaverich et al,
1988b, 1990). The activity ofthe MeHPLAase in rat uterus is stim-
ulated by oestrogens in vivo (Markaverich et al, 1989). Moreover,
MeHPLA levels in mammary cancer cells are low ornot detectable
compared with the normal counterpart (Markaverich et al, 1988a).
Therefore, changes in MeHPLAase activity and consequently in
MeHPLA levels may be involved in the regulation ofcell growth in
normal and neoplastic tissues. Recently, we observed in primary
ovarian cancer patients a significant relationship between
MeHPLAase activity in the tumour tissue and overall suvival,
suggesting a prognostic significance of this enzymatic activity in
ovarian carcinoma (Ranelletti et al, 1995).
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The prognostic clinical characterization of laryngeal squamous
cell carcinoma (SCC) is inadequate because the outcome may
differconsiderably in similar patients as regard stage and treatment
(Snow, 1989). The identification of factors related to tumour cell
biology may be useful in characterizing patients with a different
prognosis. Previous studies have identified biological factors, such
as DNA index and/or ploidy (Kearseley et al, 1991; Rua et al,
1991), or cell proliferation markers (Coltrera, 1993), which may
predict the clinical outcome of laryngeal cancer. Moreover, much
attention has been focused on the role ofoncogenes, i.e. p53, c-ras,
c-myc (Anderson et al, 1992; Irish and Bernstein, 1993; Scambia
et al, 1994; Brennan et al, 1995), cyclin DI gene amplification
(Bellacosa et al, 1996), epidermal growth factor receptor (EGFR)
expression and/or amplification (Miyaguchi et al, 1990; Santini et
al, 1991; Maurizi et al, 1992; Dassonville et al, 1993; Irish and
Bernstein, 1993; Maurizi et al, 1996).
MeHPLAase activity and consequently MeHPLA levels may be
involved in cell growth regulation in laryngeal SCC as these
tumour cells express type II EBS with ligand affinity and speci-
ficity similar to those observed for type II EBS in other malignant
tissues (unpublished observation). Therefore, we studied the clin-
ical significance of MeHPLAase activity in laryngeal SCC in a
single institution patient population with a long follow-up.
MATERIALS AND METHODS
Our study included 63 untreated consecutive primary laryngeal
SCC patients admitted to the Department ofOtolaryngology ofthe
Catholic University of Rome. All patients were staged according
to TNM classification (Hermanek and Sobin, 1992) and graded as
well (GI), moderately (G2) or poorly (G3) differentiated. At our
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institution, all primary laryngeal cancer patients received standard
therapeutic management: therapeutic surgical treatment (curative
surgery) ofthe primary tumour (T) related to the lesion extension;
therapeutic neck node dissection when there is lymph node
involvement at clinical presentation (N+) according to the 'wait
and see' policy under strict follow-up conditions; post-surgical
radiotherapy for local advanced tumours (T4); and neck lymph
node metastasis with extranodal spread. All patients of this study
have been treated according to this standard procedure. Thirty-
nine patients underwent total laryngectomy, 17 underwent supra-
glottic laryngectomy, two hemilaryngectomy and five cordectomy.
Eleven patients with advanced tumours (IT2N+, 5T4N0, 5T4N+,
stage IV) had post-surgical radiotherapy. At surgery, eight patients
with clinically positive neck nodes underwent a therapeutic neck
dissection. The median follow-up period was 50 months (range
2-90 months).
Chemicals
MeHPLA was purchased and tritiated to the specific activity of
35.2 Ci mmol-' by Amersham (Aylesbury, UK). HPLA and steroid
hormones were purchased from Sigma (St Louis, MO, USA)
and quercetin (3,3',4',5,7-pentahydroxyflavone) from Aldrich
(Steinheim, Germany).
Preparation of cytosolic and membrane fractions
Human larynx tissues were obtained at surgery. The tissue was
placed on ice for no more than 10 min until tumour tissue could be
histologically identified and excised. Samples were frozen in
liquid nitrogen immediately after surgery and stored at-80°C until
assay. In 22 patients, specimens of normal larynx mucosa were
obtained together with cancer tissues. At the time ofassays, tissues
frozen in liquid nitrogen were pulverized by a microdismembrator
(Braun, Terzano, Italy), and then resuspended by homogenizing in
TE buffer (10 mm Tris 1.5 mm EDTA) for determination of
MeHPLAase activity or in TENMG buffer [TE + sodium azide
(5 mM) monothioglycerol (0.1%), and glycerol (20%)] for
oestrogen (ER), progesterone (PR) and epidermal growth factor
(EGFR) receptors. Cytosolic and membrane fractions were
prepared, as described previously (Scambia et al, 1991), by
centrifuging the crude homogenates at 105 000g for 75 min at 2°C.
Receptor assays
ER and PR were assayed using the dextran-coated charcoal (DCC)
method according to the EORTC (1980) protocol and EGFR was
assayed as previously reported (Scambia et al, 1991). The receptor
concentrations were expressed as fmol mg-1 protein. Steroid
receptor concentration of 2 3 fmol mg-' cytosol protein was
considered the lower limit of detection for the assay, i.e. different
from zero.
Measurement of MeHPLAase activity
Cytosolic fractions diluted to 1 mg of protein ml-' in TE buffer
were assayed for MeHPLAase activity. The assay was carried out
by incubating 0.5 ml of cytosol (and TE as the control) with
[3H]MeHPLA (10 pM) for 8 min at 37°C. Preliminary experi-
ments revealed that MeHPLAase activity was linear with the time
in the range between 2 min and 10 min and in a range of protein
concentrations between 0.5 mg ml-1 and 4 mg ml-'. Competitors
were used in dimethyl sulphoxide (DMSO) as [3H]MeHPLA
hydrolysis was markedly inhibited by ethanol. After incubation,
the reaction mixture (pH 7.4) was first extracted three times with
three volumes of ethyl acetate to obtain fractions containing
[3H]MeHPLA and then acidified (pH 1.0) with hydrochloric acid
and extracted three times with 3 vol of ethyl acetate to obtain
[3H]HPLA. In experiments aimed at confirming the hydrolysis of
MeHPLA to HPLA, the ethyl acetate extracts and MeHPLA and
HPLA standards were dried under nitrogen, resuspended in 50gl
of ethyl acetate and analysed using thin-layer chromatography
on activated silica gel plates (Merck, Darmstadt, Germany).
Chromatograms were developed in hexane-ethyl acetate (1:1,
v/v), and plates were scanned for radioactivity with a Bioscan
System 200 Imaging Scanner (Packard). The ethyl acetate extracts
from neutral and from acidified samples gave a single peak of
radioactivity with Rf values of 0.41 and 0.01 respectively. The
same Rf values were obtained with unlabelled MeHPLA and with
HPLA standards. After it had been demonstrated that [3H]HPLA
was the only metabolite of [3H]MeHPLA hydrolysis, the assay
was carried out on the basis of selective ethyl acetate extraction
of [3H]MeHPLA from neutral and of [3H]HPLA from acidified
fractions. Results were expressed as pmol of [3H]MeHPLA
hydrolysed per mg ofcytosolic protein per min (pmol mg-' protein
min-'). The characteristics of MeHPLAase activity in laryngeal
tumours were similar to those previously observed in rat uterus
(Markaverich et al, 1989) and human ovarian tumours (Ranelletti
et al, 1995) in that: (a) it is very sensitive to ethanol and is almost
totally destroyed by heating; (b) it is inhibited by quercetin; and
(c) the hydrolysis of MeHPLA to HPLA is catalysed (data not
shown). For prognostic evaluation, a cut-offpoint of0.332, which
corresponded to the mean value of MeHPLAase activity distribu-
tion, was chosen to distinguish patients with low (< 0.332) from
those with high (2 0.332) esterase activity.
Statistical analysis
Correlations between ER, PR, EGFR and MeHPLAase activity
were assessed by Spearman rank correlation test. The
Mann-Whitney or Kruskal-Wallis non-parametric tests were used
to analyse the distribution of MeHPLAase activity according to
various clinicopathological parameters. Survival data were avail-
able for 63 patients. The Cox-Mantel method was used to evaluate
the prognostic role of MeHPLAase activity as a continuous vari-
able (Cox, 1972). All medians and life tables were computed using
the product-limit estimate by Kaplan and Meier (1958), and the
curves were examined by means of the log-rank test (Mantel,
1966). Multivariate analysis was performed by Cox's proportional
hazards model. Relapse-free survival was calculated from the date
of first surgery to the date of clinical or pathological local recur-
rence. Overall survival was calculated from the date of first
surgery to the date of death (median follow-up period was 50
months; range 2-90-months).
RESULTS
Figure 1 shows the distribution of MeHPLAase activity in 63
cases of laryngeal SCC. The enzymatic activity appeared to be
skewed towards the lower values (mean ± s.d.: 0.332 ± 0.379;
median: 0.145; range 0.030-1.500). ER were present in 17 out of
46 (37%) patients (mean ± s.d.: 7.49 ± 5.31; median: 6.00; range
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Figure 1 Distribution of MeHPLAase activity in 63 cases of primary
laryngeal SCC
3.10-22.30) and PR in 22 out of 46 (48%) cases (mean ± s.d.:
11.27 ± 9.79; median: 7.71; range 3.15-44.95). EGFRs
were present in 61 out of 63 (97%) patients (mean ± s.d.:
15.28 ± 25.50; median: 8.20; range 0.280-169.60). MeHPLAase
activity did not show any correlation with ER, PR and EGFR
levels (data not shown).
Table 1 shows the distribution of MeHPLAase activity
according to clinicopathological characteristics ofprimary laryn-
geal SCC. No significant relationship was observed between
MeHPLAase activity and age, sex, tumour site, T classification,
stage of disease and EGFR status, whereas a significant inverse
relationship was found between enzymatic activity and neck
lymph node positivity (N+) at presentation (P = 0.01).
Furthermore, although the difference was not statistically signifi-
cant (P = 0.08), MeHPLAase activity tended to be higher in
tumours with a low histopathological grade than as in those with a
high histopathological grade.
During the follow-up period, locoregional recurrences were
observed in 31 out of 63 (49%) cases. At the end of the study, 27
out of 63 (43%) patients had died of cancer. Cox univariate regres-
sion analysis using MeHPLAase activity as a continuous covariate
showed that the levels ofenzymatic activity were inversely associ-
ated with the risk of death (x2=4.35, P = 0.037) and relapse
(22=6.81, P = 0.0091).
Table 1 MeHPLAase activity (pmol mg-' protein min-') according to clinicopathological characteristics in 63 primary squamous laryngeal cancer patients
Number Mean Median Range P
Total 63
Age
<60 28 0.290 0.138 (0.030-1.500)
> 60 35 0.366 0.168 (0.031-1.500) 0.93
Sex
Male 58 0.347 0.154 (0.030-1.500)
Female 5 0.162 0.088 (0.067-0.413) 0.49
Tumour site
Glottic 6 0.202 0.184 (0.056-0.382)
Supraglottic 20 0.315 0.096 (0.030-1.500)
Transglottic 37 0.362 0.202 (0.046-1.500) 0.29
T classification
1 9 0.391 0.337 (0.038-0.958)
2 20 0.330 0.118 (0.046-1.500)
3 22 0.344 0.183 (0.031-1.500)
4 12 0.271 0.096 (0.030-1.500) 0.39
Lymph-node involvement
NO 55 0.358 0.168 (0.031-1.500)
N+ 8 0.156 0.067 (0.030-0.770) 0.01
Histopathological grading
Gl 13 0.462 0.413 (0.066-1.500)
G2 29 0.320 0.163 (0.030-1.500)
G3 21 0.268 0.096 (0.031-1.500) 0.08
Stage
8 0.327 0.308 (0.050-0.815)
11 14 0.380 0.147 (0.066-1.500)
III 26 0.341 0.183 (0.031-1.500)
IV 15 0.276 0.093 (0.030-1.500) 0.35
EGFR status
< 16 fmol mg-' protein 47 0.351 0.164 (0.030-1.500)
2 16 fmol mg-' protein 16 0.277 0.096 (0.046-0.851) 0.42
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Figure 2 Plots of the estimates of overall survival and relapse-free survival at 4-year follow-up as a function of the levels of MeHPLAase activity. The
proportional hazards model was evaluated at each covariate value and the proportion of patients without event at 4-year follow-up was estimated from the
computed survival functions
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Figure 3 Survival rate according to MeHPLAase status in 63 primary laryngeal cancer patients: overall survival (27 patients had died); relapse-free survival
(31 patients had local recurrence). C, MeHPLAase activity > 0.332 pmol mg-'; protein min-' 0, MeHPLAase activity < 0.332 pmol mg-' protein min-'
Figure 2 shows the plots of the estimates of the overall survival
and relapse-free survival as a function ofthe levels ofMeHPLAase
activity. At 4-year follow-up the estimated proportions of patients
still alive were 49% and 85% at 0.1 and 1.0 pmol mg-' protein
min-' enzymatic activities respectively. At the same representative
levels of MeHPLAase activities the estimated proportions of
recurrence-free patients were 35% and 85% respectively.
Figure 3 shows the survival curves according to MeHPLAase
activity status. A significant relationship was found between low
enzymatic activity and short overall survival. The 5-year survival
(Figure 3A) was 79% (95% confidence interval 60-97%) for
patients with high (2 0.332 pmol mg-' protein min-') enzymatic
activity compared to 47% (95% confidence interval: 32-62%) for
patients with low (< 0.332 pmol mg-' protein min-') enzymatic
activity (P = 0.0124). Similarly, the relapse-free survival curves
(Figure 3B) indicated that patients with high MeHPLAase activity
have a longer relapse-free survival than those with low enzymatic
activity. Thus, at the cut-off value of 0.322 pmol mg-' protein
min-', the 5-year relapse-free survival was 79% (95% confidence
interval: 60-97%) for patients with high MeHPLAase activity
compared with 34% (95% confidence interval: 19-44%) for those
with low enzymatic activity (P = 0.001).
The possibility to identify high- and low-risk cases in the
subgroup of lymph node negative patients is of clinical outmost
importance. Considering that node-negative cases represent the
vast majority of this patient population, we decided to assess
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Table 2 Univariate and multivariate analysis of prognostic variables for overall survival in 63 primary squamous laryngeal cancer patients
Univariate Multivariate
Variable RR1 (Cl 95%) X2 P RR2 (Cl 95%) x2 P
Lymph-node involvement
No 1 1
Yes 2.32 (0.93-5.76) 3.29 0.06 0.57 (0.19-1.68) 1.02 0.31
Grading
1-2 1 1
3 1.15 (0.52-2.58) 0.13 0.71 1.32 (0.49-3.54) 0.31 0.58
T classification
1-2 1 1
3-4 2.65 (1.15-6.10) 5.29 0.02 2.45 (0.92-6.51) 3.22 0.07
Age (years)
<60 1 1
>60 1.16 (0.53-2.54) 0.14 0.70 1.84 (0.71-4.75) 1.59 0.21
Tumor site
Supraglottic 1
Transglottic 1.33 (0.60-2.98) 0.50 0.48 1.17 (0.43-3.14) 0.10 0.76
EGFR status
1 1
+ 3.46 (1.61-7.45) 10.11 0.0015 3.90 (1.65-9.22) 9.61 0.002
Me-HPLAase
+ 1 1
0.28 (0.09-0.81) 5.41 0.019 3.27 (1.05-10.24) 4.16 0.04
RR1, unadjusted relative risk; RR2, relative risk taking into account all the variables in the table. Cl 95%: 95% confidence intervals.
Table 3 Univariate and multivariate analysis of prognostic variables for disease-free survival in 63 primary squamous laryngeal cancer patients
Univariate Multivariate
Variable RR1 (Cl 95%) X2 P RR2 (Cl 95%) x2 P
Lymph-node involvement
No 1 1
Yes 2.52 (1.10-5.87) 4.62 0.03 0.50 (0.19-1.30) 2.03 0.15
Grading
1-2 1 1
3 1.26 (0.60-2.62) 0.37 0.54 1.10 (0.45-2.63) 0.03 0.85
T classification
1-2 1 1
3-4 1.88 (0.90-3.94) 2.83 0.09 1.55 (0.62-3.88) 0.87 0.35
Age (years)
<60 1 1
>60 0.88 (0.43-1.80) 0.11 0.73 1.26 (0.55-2.87) 0.30 0.59
Tumour site
Supraglottic 1 1
Transglottic 1.02 (0.49-2.10) 0.02 0.96 0.90 (0.37-2.16) 0.07 0.79
EGFR status
1 1
+ 3.15 (1.53-6.48) 9.76 0.002 3.57 (1.59-8.03) 9.52 0.002
Me-HPLAase
+ 1 1
4.87 (1.69-13.98) 8.65 0.003 4.79 (1.56-14.80) 7.46 0.006
RR1, unadjusted relative risk; RR2, relative risk taking into account all the variables in the table. Cl 95%: 95% confidence intervals.
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whether MeHPLAase status is of prognostic significance in this
subgroup ofpatients. We found a significant relationship between
low MeHPLAase activity and shorter relapse-free and overall
survival. In particular, the 5-year overall survival was 51% (95%
confidence interval 35-68%) for patients with low (< 0.332 pmol
mg-' protein min-') enzymatic activity compared with 84%
(95% confidence interval: 67-100%) for patients with high
(. 0.332 pmol mg-' protein min-') enzymatic activity (P = 0.016).
Similarly, at the cut-off value of 0.332 pmol mg-' protein min-',
the5-yearrelapse-free survival was 38% (95% confidence interval:
22-55%) for patients with low enzymatic activity compared with
84% (95% confidence interval: 67-100%) for those with high
enzymatic activity (P = 0.002).
In Tables 2 and 3, univariate and multivariate analysis of prog-
nostic variables for overall and relapse-free survival are shown.
Cases with high EGFR, low MeHPLAase activity, T3-T4 stage
and lymph node positivity showed a significantly increased risk of
death andrelapse. In the multivariate analysis EGFRpositivity and
MeHPLAase activity retained an independent negative prognostic
significance.
DISCUSSION
This report describes for the first time the presence and character-
istics ofMeHPLAase activity in a large series ofprimary laryngeal
SCC.
The characteristics of MeHPLAase were similar to those
described in ovarian cancers (Ranelletti et al, 1995) relative to the
high sensitivity of enzymatic activity to ethanol and heating and
the susceptibility to be inhibited by quercetin.
The enzymatic activity was higher in laryngeal SCC (median
0.145; range: 0.03-1.500) than in ovarian cancers (median: 0.062;
range: 0-0.429). Moreover, in contrast to what was observed in
ovarian cancers, in laryngeal SCC MeHPLAase activity did not
correlate either with ER or with PR levels. Taken together, these
observations suggest that MeHPLAase activity can be regulated in
a tissue-specific manner.
High levels of MeHPLAase activity were associated in laryn-
geal SCC with a less aggressive behaviour in terms ofoverall and
relapse-free survival. These findings were similar to those previ-
ously obtained in ovarian cancers (Ranelletti et al, 1995), with the
exception that in laryngeal cancer MeHPLAase activity is a better
predictor ofrecurrence than ofdeath.
As MeHPLAase metabolizes the endogenous type II EBS ligand
displaying cell growth inhibitory activity, it was surprising that
low enzymatic activity was associated with a worse prognosis.
MeHPLA and MeHPLAase can be considered an interesting system
of regulation of cell proliferation, but its specific biological role in
normal and tumour cell growth is still far from being clarified.
In conclusion, considering that there are only a few biological
parameters for the prognostic characterization of laryngeal SCC,
our findings could be useful as they add a new independent para-
meter for identifying high-risk patients for a more radical therapy.
Moreover, among the biological parameters studied to date,
MeHPLAase status represents the first prognostic indicator that is
able to discriminate high- and low-risk patients in the lymph node-
negative subgroup.
Studies on a large series of patients are needed to further
confirm these results and to better clarify the role ofthis enzymatic
system in laryngeal cancer cell biology.
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